755 results on '"hereditary breast and ovarian cancer"'
Search Results
102. A pathogenic germline BRCA1 mutation identified in a patient with non-Hodgkin lymphoma and rectal adenocarcinoma: "Non-classical" hereditary cancer?
- Author
-
Zhou, You, Xu, Yanjie, Zhao, Jiemin, and Hu, Wenwei
- Published
- 2023
- Full Text
- View/download PDF
103. Precision medicine for hereditary tumors in gynecologic malignancies.
- Author
-
Sekine, Masayuki and Enomoto, Takayuki
- Subjects
- *
THERAPEUTIC use of antineoplastic agents , *IMMUNE checkpoint inhibitors , *BRCA genes , *HETEROCYCLIC compounds , *INDIVIDUALIZED medicine , *GENETIC disorders , *CANCER relapse , *PREVENTIVE health services , *FEMALE reproductive organ tumors , *IMMUNOTHERAPY , *THERAPEUTICS - Abstract
Genomic medicine for gynecologic tumors is characterized by hereditary breast and ovarian cancer (HBOC) and Lynch syndrome (LS). Poly ADP‐ribose polymerase (PARP) inhibitor, olaparib, and the immune checkpoint inhibitor, pembrolizumab, which are drugs that show sensitivity to each hereditary tumor, have begun to spread in clinical practice for gynecologic malignancies. In clinical use, platinum sensitivity is used as a clinical surrogate marker for olaparib sensitivity, and microsatellite instability is used as a biological surrogate marker for pembrolizumab sensitivity. BRCA genetic testing and microsatellite instability test have been used as companion diagnostics before starting olaparib and pembrolizumab treatment, respectively. Homologous recombination deficiency test could be used for companion diagnostic of olaparib combination with bevacizumab in first‐line maintenance treatment and niraparib without re‐administration of platinum agents in the treatment of recurrence. The approval of the three drugs has been changing the treatment of gynecologic malignancies. Furthermore, preventive medical care has been covered by insurance since April 2020 for breast and/or ovarian cancer patients with germline BRCA1/2 mutation in Japan. This review article outlines the current status and future prospects of precision medicine for gynecologic hereditary tumors focusing on HBOC and LS. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
104. Hereditary Breast and Ovarian Cancer Service in Sparsely Populated Western Pomerania
- Author
-
Ute Felbor, Robin Bülow, Rita K. Schmutzler, and Matthias Rath
- Subjects
hereditary breast and ovarian cancer ,genetic counseling ,diagnostic and predictive genetic analyses ,risk-adapted prevention ,rural area ,Medicine - Abstract
The German Consortium Hereditary Breast and Ovarian Cancer (GC-HBOC) consists of 23 academic centers striving to provide high-quality regional care for affected individuals and healthy at-risk family members. According to the standard operating procedures defined by the GC-HBOC, a Familial Breast and Ovarian Cancer Center was implemented at the University Medicine Greifswald over a four-year period from 2018 to 2021, despite the COVID-19 pandemic. Genetic analyses were performed in a total of 658 individuals, including 41 males, which paved the way to local annual risk-adapted breast cancer surveillance for 91 women and prophylactic surgery for 34 women in 2021. Our experience in the North Eastern part of Germany demonstrates that it is possible to establish a high-risk breast and ovarian cancer service even in a sparsely populated region. Major facilitators are the interdisciplinary collaboration of dedicated local experts, the support of the GC-HBOC, fruitful clinical and scientific cooperations and the use of technical improvements. As a blueprint, our project report may help to further expand the network of specialized and knowledge-generating care for HBOC families.
- Published
- 2022
- Full Text
- View/download PDF
105. Development of decision aids for female BRCA1 and BRCA2 mutation carriers in Germany to support preference-sensitive decision-making.
- Author
-
Kautz-Freimuth, Sibylle, Redaèlli, Marcus, Rhiem, Kerstin, Vodermaier, Andrea, Krassuski, Lisa, Nicolai, Kathrin, Schnepper, Miriam, Kuboth, Violetta, Dick, Julia, Vennedey, Vera, Wiedemann, Regina, Schmutzler, Rita, and Stock, Stephanie
- Subjects
- *
BRCA genes , *BREAST cancer , *MEDICAL specialties & specialists , *OVARIAN cancer , *MEDICAL research , *FALLOPIAN tubes - Abstract
Background: Women with pathogenic BRCA1 and BRCA2 mutations possess a high risk of developing breast and ovarian cancer. They face difficult choices when considering preventive options. This study presents the development process of the first decision aids to support this complex decision-making process in the German healthcare system.Methods: A six-step development process based on the International Patient Decision Aid Standards was used, including a systematic literature review of existing decision aids, a topical medical literature review, preparation of the decision aids, focus group discussions with women with BRCA1/2 mutations, internal and external reviews by clinical and self-help experts, and user tests. All reviews were followed by iterative revisions.Results: No existing decision aids were transferable to the German setting. The medical research revealed a need to develop separate decision aids for women with BRCA1/2 mutations (A) without a history of cancer (previvors) and (B) with a history of unilateral breast cancer (survivors). The focus group discussions confirmed a high level of approval for the decision aids from both target groups. Additionally, previvors requested more information on risk-reducing breast surgery, risk-reducing removal of both ovaries and Fallopian tubes, and psychological aspects; survivors especially wanted more information on breast cancer on the affected side (e.g. biological parameters, treatment, and risk of recurrence).Conclusions: In a structured process, two target-group-specific DAs for previvors/survivors with BRCA1/2 mutations were developed to support decision-making on risk-adapted preventive options. These patient-oriented tools offer an important addition to existing specialist medical care in Germany. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
106. Genetic counselor approaches to BRCA1/2 direct‐to‐consumer genetic testing results.
- Author
-
Burke, Sarah, Mork, Maureen, Qualmann, Krista, Woodson, Ashley, Jin Ha, Min, Arun, Banu, and Kaulfus, Meagan
- Abstract
The National Comprehensive Cancer Network recommends clinical‐grade genetic testing to confirm commercial results from direct‐to‐consumer genetic testing (DTC‐GT) companies and third‐party interpretation (TPI) services; however, the type of confirmatory testing that genetic counselors (GCs) recommend remains uncharacterized. Therefore, we aimed to describe GCs testing strategies for patients who have already obtained DTC‐GT results (23andMe) or TPI data (Promethease) that reported a BRCA1/2 pathogenic variant. We invited GCs specializing in clinical cancer genetics to complete an online survey distributed to members of the National Society of Genetic Counselors. The survey, completed by 80 respondents, contained case scenarios featuring probands with variable personal and family histories of cancer. Our results show that the majority of participating GCs have counseled patients for their health‐related commercial test results; 94% have encountered patient DTC‐GT reports (3 per year), and 69% have encountered patient TPI data (2 per year). Most participating GCs would recommend confirmatory clinical‐grade testing for probands with a positive 23andMe BRCA1/2 result (77/80, 96%). However, there was strong variability between the type of recommended testing. Approximately 20% recommended single‐site analysis, 11%–14% recommended the three Ashkenazi Jewish BRCA1/2 founder mutations, 4% recommended BRCA1/2 testing, and 61%–64% recommended multi‐gene panel testing. The most commonly recommended panels were split between a breast and gynecological cancer‐focused panel and a broad pan‐cancer panel. The majority of participants (98%–100%) would also recommend confirmatory testing for patients with positive TPI data for BRCA1/2. Similarly, results were mixed between those who recommended targeted, single‐site analysis (10%–15%) compared to a multi‐gene panel (72%–83%). These data show that while most GCs were uniform in their practice of recommending confirmatory testing, they are mixed in their approach to the specific type of testing they would select. These results may help inform counseling approaches and consensus for this expanding group of patients. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
107. Process evaluation of a culturally targeted video for Latinas at risk of hereditary breast and ovarian cancer.
- Author
-
Hurtado‐de‐Mendoza, Alejandra, Gómez‐Trillos, Sara, Graves, Kristi D., Carrera, Pilar, Campos, Claudia, Anderson, Lyndsay, Gronda, Andrés, Orellana, Halyn, Peshkin, Beth N., Schwartz, Marc D., Cupertino, Paula, Ostrove, Nancy, Luta, George, Gonzalez, Nathaly, and Sheppard, Vanessa B.
- Abstract
This paper presents a process evaluation of a culturally targeted narrative video about hereditary breast and ovarian cancer (HBOC) for Latina women at risk for HBOC. Spanish‐speaking Latina women at risk for HBOC participated in a single arm study (n = 40). Participants watched the video developed by the authors and responded to surveys. We used mixed methods to assess theoretical constructs that are hypothesized mediators of narrative interventions (i.e., transportation or engagement, identification with characters, emotions) and implementation outcomes (e.g., acceptability). Descriptive statistics summarized theoretical constructs and implementation outcomes. We conducted Mann–Whitney U tests to assess the differences in theoretical and implementation outcomes between participants who were affected versus. unaffected and participants with different levels of education and health literacy. We used the consensual qualitative research framework to analyze qualitative data. Participants' mean age was 47.1 years (SD = 9.48). Most participants were high school graduates or less (62.5%). Acceptability of the video was extremely high (Md = 10.0, IQR = 0.2, scale 1–10). Most (82.5%) suggested video dissemination be through social media. Participants were highly engaged (Md = 5.7, IQR = 1.5, scale 1–7), strongly identified with the main character (Md = 8.7, IQR = 2.6, scale 1–10), and reported experiencing mostly positive emotions (Md = 9.5, IQR = 2.8, scale 1–10). Participants with low health literacy and affected participants reported a significantly higher identification with the main character (p<.05). Qualitative data reinforced the quantitative findings. Women reported gaining knowledge, correcting misconceptions, and feeling empowered. Our culturally targeted video is highly acceptable and targets mechanisms of behavior change for narrative interventions. The video is easily disseminable and can be used as an education tool for patients including affected and unaffected women and patients with different education and health literacy levels. Future studies should test the impact of the video in enhancing genetic counseling and testing uptake. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
108. The results of multigene panel sequencing in Slovak HBOC families.
- Author
-
KONECNY, Michal, KOSOVA, Klaudia, TILANDYOVA, Petra, WACHSMANNOVA, Lenka, BALDOVIC, Marian, KRAJCOVIC, Juraj, PATLEVICOVA, Andrea, MARKUS, Jan, and CIERNIKOVA, Sona
- Subjects
BRCA genes ,HEREDITARY cancer syndromes ,CANCER genetics ,CANCER treatment ,CANCER cell growth - Abstract
Hereditary breast and ovarian cancer (HBOC) is primarily associated with mutations in the BRCA1/2 genes. However, causal variants in other high, moderate, and low penetrance genes proportionally increase the risk of breast/ovarian cancer. This study aims to provide data about the mutation spectrum of HBOC-associated genes in Slovak HBOC families and estimate the ratio of BRCA versus non-BRCA causal variants. We used panel sequencing containing 22 high/moderate-risk susceptibility genes and parallel MLPA analysis of BRCA1/2, CHEK2 genes, to analyze 94 individuals with a strong family/personal history of breast and/or ovarian cancer. The analyzed group consisted of 80 patients diagnosed with cancer (85.1%) and 14 healthy individuals (14.9%) with a positive family history of HBOC syndrome. In total, we have identified 22 causal DNA variants (23.4%) showing 15 primary findings in BRCA1/2 genes (68.2%) and 7 positive secondary findings in CHEK2, PALB2, CDH1, and MUTYH genes (31.8%). The most frequent pathogenic alterations were BRCA1 mutations c.181T>G and CNV variant (c.5573-?_c.5701+?)del, known as deletion of exons 21-22. Besides known mutations, the BRCA1 variant c.2794del (p.Val932Leufs*68) and variant c.2480dup (p.Tyr827*) in the CDH1 gene represent the novel, previously unpublished variants that might be population-specific. In conclusion, we provide the first report of multigene panel testing in Slovak HBOC families demonstrating that almost one-third of pathogenic mutations are situated in susceptibility genes other than BRCA1/2. Although multigene panel testing requires precise data filtration and interpretation, it might bring the relevant data for clinical management of the patients. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
109. Quality and Quantity: How to Organize a Countrywide Genetic Counseling and Testing.
- Author
-
Schmutzler, Rita Katharina
- Subjects
BREAST tumor prevention ,MEDICAL quality control ,OVARIAN tumors ,GENETIC testing ,PREVENTIVE health services ,INTELLECT ,GENETIC counseling ,BREAST tumors - Abstract
Background: About 30% of all women with breast or ovarian cancer exhibit a family history of the disease. So far, the genetic cause could be deciphered in about 30% of these cases. The results demonstrate a high genetic heterogeneity, with high-risk and moderate-risk genes and low-risk variants contributing alone or in concert to the development of cancer. Furthermore, it has been shown that the genotype significantly determines the phenotype and that knowledge of the phenotype is as important as the genotype to offer adequate and risk-adapted prevention to persons at risk. For newly identified risk genes, however, the phenotype is not sufficiently characterized at first, and thus prevention measures are not sufficiently evaluated. Summary: The German Consortium for Hereditary Breast and Ovarian Cancer has developed a concept for collecting the missing data in the context of knowledge-generating care and at the same time ensuring care based on the best available knowledge. Core elements of this concept are: structured and standardized care, an outcome-oriented evaluation based on a comprehensive registry, networking with certified breast and gynecological cancer centers combined with regular training on state-of-the-art care for doctors, and compilation of comprehensible patient information. This comprehensive concept has been incorporated into contracts for specialized care with health insurers and thus ensures nationwide care at the highest scientific and clinical levels. Key Messages: This article describes how to implement a concept of evidence-generating care for risk-adjusted prevention in a nationwide health care system. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
110. Effectiveness of decision aids for female BRCA1 and BRCA2 mutation carriers: a systematic review
- Author
-
Lisa Krassuski, Vera Vennedey, Stephanie Stock, and Sibylle Kautz-Freimuth
- Subjects
BRCA1 and BRCA2 ,Female BRCA1 and BRCA2 mutation carriers ,Familial breast cancer ,Familial ovarian cancer ,Hereditary breast and ovarian cancer ,HBOC ,Computer applications to medicine. Medical informatics ,R858-859.7 - Abstract
Abstract Background Female BRCA1 and BRCA2 mutation carriers have an increased lifetime risk of developing breast and/or ovarian cancer. Hence, they face the difficult decision of choosing a preventive strategy such as risk-reducing surgeries or intensified breast screening. To help these women during their decision process, several patient decision aids (DA) were developed and evaluated in the last 15 years. Until now, there is no conclusive evidence on the effectiveness of these DA. This study aims 1) to provide the first systematic literature review about DA addressing preventive strategy decisions for female BRCA1 and BRCA2 mutation carriers, 2) to analyze the quality of the existing evidence, 3) to evaluate the effects of DA on decision and information related outcomes, on the actual choice for preventive measure and on health outcomes. Methods A systematic literature review was conducted using six electronic databases (inclusion criteria: DA addressing preventive strategies, female BRCA1 and BRCA2 mutation carriers, 18 to 75 years, knowledge of test result). The quality of the included randomized controlled trials (RCT) was evaluated with the Cochrane Collaboration’s risk of bias tool. The quality of included one-group pretest-posttest design studies was evaluated with the ROBINS-I tool. Outcomes of included studies were extracted and qualitatively summarized. Results A total of 2093 records were identified. Six studies were included for further evaluation (5 RCT, 1 one-group pretest-posttest design study). One RCT was formally included, but data presentation did not allow for further analyses. The risk of bias was high in three RCT and unclear in one RCT. The risk of bias in the one-group pretest-posttest study was serious. The outcome assessment showed that the main advantages of DA are linked to the actual decision process: Female BRCA1 and BRCA2 mutation carriers using a DA had less decisional conflict, were more likely to reach a decision and were more satisfied with their decision. Conclusions Decision aids can support female BRCA1 and BRCA2 mutation carriers during their decision process by significantly improving decision related outcomes. More high-quality evidence is needed to evaluate possible effects on information related outcomes, health outcomes and the actual choice for preventive measures.
- Published
- 2019
- Full Text
- View/download PDF
111. Validation of a digital identification tool for individuals at risk for hereditary cancer syndromes
- Author
-
Leslie Bucheit, Katherine Johansen Taber, and Kaylene Ready
- Subjects
BRCA1 ,BRCA2 ,Hereditary breast and ovarian Cancer ,Lynch syndrome ,Hereditary cancer ,Family history screening. Risk assessment ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 ,Genetics ,QH426-470 - Abstract
Abstract Background The number of individuals meeting criteria for genetic counseling and testing for hereditary cancer syndromes (HCS) is far less than the number that actually receive it. To facilitate identification of patients at risk for HCS, Counsyl developed a digital identification tool (digital ID tool) to match personal and family cancer history to National Comprehensive Cancer Network (NCCN) BRCA-related Hereditary Breast and Ovarian Cancer (HBOC), Lynch syndrome, and polyposis testing criteria in one-to-one, automated fashion. The purpose of this study was to validate the ability of the digital ID tool to accurately identify histories that do and do not meet NCCN testing criteria. Methods Third-party recorded three-generation pedigrees were retrospectively reviewed by a certified genetic counselor (CGC) to determine if independent events included in pedigree histories met NCCN guidelines, and were then sorted into groups: high risk events (meets criteria) and low risk events (does not meet criteria). Events were entered into the digital ID tool to determine the extent of its concordance with events sorted by CGC review. Statistical tests of accuracy were calculated at a 95% confidence interval (CI). Results One hundred ninety-seven pedigrees were reviewed consecutively representing 765 independent events for analysis across groups. 382/382 (100%) high risk events identified by the digital ID tool and 381/383 (99.47%) low risk events identified by the digital ID tool were concordant with CGC sorting. The digital ID tool had a sensitivity of 100% (99.04–100% CI) and specificity of 99.48% (98.13–99.94% CI). The overall accuracy of the digital ID tool was estimated to be 99.74% (99.06–99.97% CI), reflecting the rate at which the digital ID tool reached the same conclusion as that of CGC review of pedigree events for the recommendation of genetic testing for individuals at risk for HCS. Conclusions The digital ID tool accurately matches NCCN criteria in one-to-one fashion to identify at-risk individuals for HCS and may be useful in clinical practice, specifically for BRCA-related HBOC and Lynch Syndrome.
- Published
- 2019
- Full Text
- View/download PDF
112. Hereditary Ovarian and Endometrial Cancers: Current Management
- Author
-
Hirasawa, Akira, Aoki, Daisuke, Konishi, Ikuo, Series editor, and Katabuchi, Hidetaka, Series editor
- Published
- 2017
- Full Text
- View/download PDF
113. BRCA1/2 mutations and risk‐reducing bilateral salpingo‐oophorectomy among Latinas: The UPTAKE study.
- Author
-
Lynce, Filipa, Schlam, Ilana, Geng, Xue, Peshkin, Beth N., Friedman, Sue, Dutil, Julie, Nahleh, Zeina, Campos, Claudia, Ricker, Charité, Rodriguez, Patricia, Denduluri, Neelima, Ahn, Jaeil, Isaacs, Claudine, and Graves, Kristi D.
- Abstract
Bilateral salpingo‐oophorectomy (BSO) is a risk management approach with strong evidence of mortality reduction for women with germline mutations in the tumor suppressor genes BRCA1 and BRCA2 (BRCA1/2). Few studies to date have evaluated uptake of BSO in women from diverse racial and ethnic backgrounds who carry BRCA1/2 mutations. The objective of the UPTAKE study was to explore rates and predictors of risk‐reducing BSO among Latinas affected and unaffected with breast cancer who had a deleterious BRCA1/2 mutation. We recruited 100 Latina women with deleterious BRCA1/2 mutations from community hospitals, academic health systems, community, and advocacy organizations. Women completed interviews in Spanish or English. We obtained copies of genetic test reports for participants who provided signed medical release. After performing threefold cross‐validation LASSO for variable selection, we used multiple logistic regression to identify demographic and clinical predictors of BSO. Among 100 participants, 68 had undergone BSO at the time of interview. Of these 68, 35 were US‐born (61% of all US‐born participants) and 33 were not (77% of the non‐US‐born participants). Among Latinas with BRCA1/2 mutations, older age (p = 0.004), personal history of breast cancer (p = 0.003), higher income (p = 0.002), and not having a full‐time job (p = 0.027) were identified as variables significantly associated with uptake of BSO. Results suggest a high rate of uptake of risk‐reducing BSO among a sample of Latinas with BRCA1/2 mutations living in the US. We document factors associated with BSO uptake in a diverse sample of women. Relevant to genetic counseling, our findings identify possible targets for supporting Latinas' decision‐making about BSO following receipt of a positive BRCA1/2 test. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
114. The disease sites of female genital cancers of BRCA1/2-associated hereditary breast and ovarian cancer: a retrospective study.
- Author
-
Mitamura, Takashi, Sekine, Masayuki, Arai, Masami, Shibata, Yuka, Kato, Momoko, Yokoyama, Shiro, Yamashita, Hiroko, Watari, Hidemichi, Yabe, Ichiro, Nomura, Hiroyuki, Enomoto, Takayuki, and Nakamura, Seigo
- Subjects
- *
OVARIAN cancer , *BREAST cancer , *HEREDITARY cancer syndromes , *FEMALE reproductive organs , *GENITALIA , *GENITAL diseases - Abstract
Disease sites of female genital tract cancers of BRCA1/2-associated hereditary breast and ovarian cancer (HBOC) are less understood than non-hereditary cancers. We aimed to elucidate the disease site distribution of genital cancers in women with the germline BRCA1 and BRCA2 pathogenic variants (BRCA1+ and BRCA2+) of HBOC. For the primary disease site, the proportion of fallopian tube and peritoneal cancer was significantly higher in BRCA2+ (40.5%) compared with BRCA1+ (15.4%) and BRCA− (no pathogenic variant, 12.8%). For the metastatic site, the proportion of peritoneal dissemination was significantly higher in BRCA1+ (71.9%) than BRCA− (55.1%) and not different from BRCA2+ (71.4%). With one of the most extensive patients, this study supported the previous reports showing that the pathogenic variants of BRCA1/2 were involved in the female genitalia's disease sites. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
115. Genetic counselors' perspectives on population‐based screening for BRCA‐related hereditary breast and ovarian cancer and Lynch syndrome.
- Author
-
De Simone, Lenika M., Arjunan, Aishwarya, Vogel Postula, Kristen J., Maga, Tara, and Bucheit, Leslie A.
- Abstract
Early identification of those with BRCA‐related Hereditary Breast and Ovarian Cancer Syndrome (HBOC) and Lynch syndrome has the potential for early cancer detection and/or prevention; as such, these conditions are considered Tier 1 genetic conditions by the U.S. Center for Disease Control and Prevention. Given the decreasing cost of genetic testing, population‐based screening (PBS) for such conditions may be the next step toward cancer prevention. This study aimed to understand genetic counselors' perspectives toward offering PBS for the Tier 1 conditions BRCA‐related HBOC and Lynch syndrome. An online survey was distributed to 3,609 members of the National Society of Genetic Counselors. A total of 367 individuals participated in the study. Fifty percent of respondents felt that PBS for inherited cancer should not be offered; 93.3% felt that the current healthcare system is unprepared for implementation of PBS. However, most respondents agreed that PBS should be implemented within the next 10 years. Attitudes toward offering PBS were associated with respondents' work setting, cancer specialization, and perceived preparedness (p's < 0.05). The most commonly reported barriers to the implementation of PBS were shortage of genetic professionals and lack of infrastructure. Data in this study provide evidence that infrastructural barriers and educational gaps of non‐genetic professionals would need to be addressed before successful integration of PBS into the healthcare system. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
116. Mutational Landscape for Indian Hereditary Breast and Ovarian Cancer Cohort Suggests Need for Identifying Population Specific Genes and Biomarkers for Screening
- Author
-
Mohammed Shaad N. Kadri, Komal M. Patel, Poonam A. Bhargava, Franky D. Shah, Nutan V. Badgujar, Bhoomi V. Tarapara, Prabhudas S. Patel, Mohammed Inayatullah Shaikh, Krati Shah, Apurva Patel, Shashank Pandya, Hemangini Vora, Chaitanya G. Joshi, and Madhvi N. Joshi
- Subjects
genetic testing ,next generation sequencing ,amplicon sequencing ,non-BRCA genes ,customized multi-gene panel ,hereditary breast and ovarian cancer ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
BackgroundBreast and ovarian cancers are the most prevalent cancers and one of the leading causes of death in Indian women. The healthcare burden of breast and ovarian cancers and the rise in mortality rate are worrying and stress the need for early detection and treatment.MethodsWe performed amplicon sequencing of 144 cases who had breast/ovarian cancer disease (total 137 cases are patients and seven are tested for BRCA1/2 carrier) Using our custom designed gene panel consisting of 14 genes, that are associated with high to moderate risk of breast and ovarian cancers. Variants were called using Torrent Variant Caller and were annotated using ThermoFisher’s Ion Reporter software. Classification of variants and their clinical significance were identified by searching the variants against ClinVar database.ResultsFrom a total of 144 cases, we were able to detect 42 pathogenic mutations in [40/144] cases. Majority of pathogenic mutations (30/41) were detected in BRCA1 gene, while (7/41) pathogenic mutations were detected in BRCA2 gene, whereas, (2/41) pathogenic mutations were detected in TP53 gene and BRIP1, PALB2, and ATM genes respectively. So, BRCA genes contributed 88.09% of pathogenic mutations, whereas non-BRCA genes contributed 11.91% of pathogenic mutations. We were also able to detect 25 VUS which were predicted to be damaging by in silico prediction tools.ConclusionEarly detection of cancers in the Indian population can be done by genetic screening using customized multi-gene panels. Indications of our findings show that in the Indian population, apart from the common BRCA genes, there are other genes that are also responsible for the disease. High frequency mutations detected in the study and variants of uncertain significance predicted to be damaging by in silico pathogenicity prediction tools can be potential biomarkers of hereditary breast and ovarian cancer in Indian HBOC patients.
- Published
- 2021
- Full Text
- View/download PDF
117. Family communication of BRCA1/2 results and family uptake of BRCA1/2 testing in a diverse population of BRCA1/2 carriers.
- Author
-
Fehniger, Julia, Lin, Feng, Beattie, Mary S, Joseph, Galen, and Kaplan, Celia
- Subjects
Humans ,Breast Neoplasms ,Heterozygote Detection ,Mutation ,Genes ,BRCA1 ,Genes ,BRCA2 ,Genetic Testing ,Genetic Carrier Screening ,BRCA1 ,BRCA2 ,Hereditary breast and ovarian cancer ,Family communication ,Family testing ,Disparities ,Genes ,Genetics & Heredity ,Clinical Sciences - Abstract
Previous studies examining communication of BRCA1/2 results with relatives and family uptake of BRCA1/2 testing have sampled from predominantly white, high SES cohorts ascertained solely from tertiary care centers. No studies have focused on family communication and testing among relatives of diverse BRCA1/2 carriers. We conducted structured interviews with 73 BRCA1/2 carriers identified at a public hospital and a tertiary cancer center. We asked participants if each first- and second-degree relative was aware of their BRCA1/2 results and whether or not each relative had tested. Generalized estimating equations identified rates and predictors of family communication and testing. Participants disclosed their test results to 73 % of 606 eligible relatives and 31 % of 514 eligible relatives tested. Communication and testing rates were similar for relatives of participants from the public hospital and the tertiary cancer center. Hospital site was not a significant predictor of either result disclosure or relative uptake of testing. African American and Asian/Pacific Islander participants were significantly less likely to disclose their results to their relatives; relatives of African American participants were significantly less likely to test. Addressing these disparities will require further research into the best ways to facilitate family communication and counsel at-risk relatives of racially and socioeconomically diverse BRCA1/2 mutation carriers.
- Published
- 2013
118. Mutational Landscape for Indian Hereditary Breast and Ovarian Cancer Cohort Suggests Need for Identifying Population Specific Genes and Biomarkers for Screening.
- Author
-
Kadri, Mohammed Shaad N., Patel, Komal M., Bhargava, Poonam A., Shah, Franky D., Badgujar, Nutan V., Tarapara, Bhoomi V., Patel, Prabhudas S., Shaikh, Mohammed Inayatullah, Shah, Krati, Patel, Apurva, Pandya, Shashank, Vora, Hemangini, Joshi, Chaitanya G., and Joshi, Madhvi N.
- Subjects
HEREDITARY cancer syndromes ,OVARIAN cancer ,BREAST cancer ,BRCA genes ,BIOMARKERS ,GENETIC testing - Abstract
Background: Breast and ovarian cancers are the most prevalent cancers and one of the leading causes of death in Indian women. The healthcare burden of breast and ovarian cancers and the rise in mortality rate are worrying and stress the need for early detection and treatment. Methods: We performed amplicon sequencing of 144 cases who had breast/ovarian cancer disease (total 137 cases are patients and seven are tested for BRCA1/2 carrier) Using our custom designed gene panel consisting of 14 genes, that are associated with high to moderate risk of breast and ovarian cancers. Variants were called using Torrent Variant Caller and were annotated using ThermoFisher's Ion Reporter software. Classification of variants and their clinical significance were identified by searching the variants against ClinVar database. Results: From a total of 144 cases, we were able to detect 42 pathogenic mutations in [40/144] cases. Majority of pathogenic mutations (30/41) were detected in BRCA1 gene, while (7/41) pathogenic mutations were detected in BRCA2 gene, whereas, (2/41) pathogenic mutations were detected in TP53 gene and BRIP1, PALB2, and ATM genes respectively. So, BRCA genes contributed 88.09% of pathogenic mutations, whereas non-BRCA genes contributed 11.91% of pathogenic mutations. We were also able to detect 25 VUS which were predicted to be damaging by in silico prediction tools. Conclusion: Early detection of cancers in the Indian population can be done by genetic screening using customized multi-gene panels. Indications of our findings show that in the Indian population, apart from the common BRCA genes, there are other genes that are also responsible for the disease. High frequency mutations detected in the study and variants of uncertain significance predicted to be damaging by in silico pathogenicity prediction tools can be potential biomarkers of hereditary breast and ovarian cancer in Indian HBOC patients. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
119. ERCC3, a new ovarian cancer susceptibility gene?
- Author
-
Stradella, Agostina, del Valle, Jesús, Rofes, Paula, Vargas-Parra, Gardenia, Salinas, Mónica, González, Sara, Montes, Eva, López-Doriga, Adriana, Gómez, Carolina, de Cid, Rafael, Darder, Esther, Teulé, Alex, Solanes, Ares, Munté, Elisabet, Capellà, Gabriel, Pineda, Marta, Feliubadaló, Lidia, Brunet, Joan, and Lázaro, Conxi
- Subjects
- *
GENETICS of disease susceptibility , *BREAST tumor risk factors , *ALLELES , *CANCER genetics , *CONFIDENCE intervals , *DNA , *GENETICS , *JEWS , *GENETIC mutation , *NUCLEOTIDES , *OVARIAN tumors , *PROTEINS , *RISK assessment , *GENETIC testing , *GENOMICS , *STATISTICAL significance , *BRCA genes , *DESCRIPTIVE statistics , *ODDS ratio , *DISEASE risk factors - Abstract
Hereditary breast and ovarian cancer syndrome (HBOC) is an inherited disorder with an increased risk of breast cancer (BC) and ovarian cancers (OC). Mutations in BRCA1 - BRCA2 explains less than a half of cases. In the last decade several genes with different penetrance have been associated with an increased risk of BC or OC. A recurrent heterozygous ERCC3 truncating mutation increases the risk for breast cancer in patients with Ashkenazi Jewish ancestry. Our study aimed to investigate the role of ERCC3 truncating variants in a cohort of patients with suspicion of HBOC. ERCC3 screening by multigene-panel analysis in 1311 unrelated patients after our regional consensus for genetic testing in hereditary cancer was done. In addition, 453 Spanish cancer-free individuals and 51,343 GnomAD non-Finnish, non-cancer European individuals were used as control populations. We identified 13 patients with heterozygous ERCC3 truncating variants (0.99%). Five of them also carried a mutation in a high- /moderate-penetrance HBOC gene (BRCA1 , BRCA2 , CHEK2 , and TP53) being Multilocus Inherited Neoplasia Alleles syndrome (MINAS) patients. The frequency in 453 Spanish controls was of 0.22%; similar to that observed in 51,343 non-Finnish European GnomAD population (0.24%). We found an almost statistically significant association of truncating ERCC3 variants with BC (odds ratio [OR] = 2.25, confidence interval [CI] = 0.6–5.93, P = 0.11), and we observed for the first time a significant association with OC (OR = 4.74, CI = 1–14.34, P = 0.028), that holds even after removing MINAS cases. To our knowledge, this is the largest HBOC series comprehensively analysed for ERCC3 mutations, and the first study identifying ERCC3 as a cancer risk for OC. • Our results confirm the association of ERCC3 truncating mutations with breast cancer. • We also describe their association with ovarian cancer for the first time. Further studies in larger cohorts are needed to more precisely establish the associated cancer risk as well as the relation with other cancer types. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
120. A dominant RAD51C pathogenic splicing variant predisposes to breast and ovarian cancer in the Newfoundland population due to founder effect
- Author
-
Lesa M. Dawson, Kerri N. Smith, Salem Werdyani, Robyn Ndikumana, Cindy Penney, Louisa L. Wiede, Kendra L. Smith, Justin A. Pater, Andrée MacMillan, Jane Green, Sheila Drover, Terry‐Lynn Young, and Darren D. O’Rielly
- Subjects
founder variant ,hereditary breast and ovarian cancer ,RAD51C ,splicing ,variant of uncertain significance ,Genetics ,QH426-470 - Abstract
Abstract Background RAD51C is important in DNA repair and individuals with pathogenic RAD51C variants have increased risk of hereditary breast and ovarian cancer syndrome (HBOC), an autosomal dominant genetic predisposition to early onset breast and/or ovarian cancer. Methods Five female HBOC probands sequenced negative for moderate‐ and high‐risk genes but shared a recurrent variant of uncertain significance in RAD51C (NM_058216.3: c.571 + 4A > G). Participant recruitment was followed by haplotype and case/control analyses, RNA splicing analysis, gene and protein expression assays, and Sanger sequencing of tumors. Results The RAD51C c.571 + 4A > G variant segregates with HBOC, with heterozygotes sharing a 5.07 Mbp haplotype. RAD51C c.571 + 4A > G is increased ~52‐fold in the Newfoundland population compared with the general Caucasian population and positive population controls share disease‐associated alleles, providing evidence of a founder effect. Splicing analysis confirmed in silico predictions that RAD51C c.571 + 4A > G causes exon 3 skipping, creating an immediate premature termination codon. Gene and protein expression were significantly reduced in a RAD51C c.571 + 4G > A heterozygote compared with a wild‐type relative. Sanger sequencing of tumors from two probands indicates loss‐of‐heterozygosity, suggesting loss of function. Conclusion The RAD51C c.571 + 4A > G variant affects mRNA splicing and should be re‐classified as pathogenic according to American College of Medical Genetics and Genomics guidelines.
- Published
- 2020
- Full Text
- View/download PDF
121. Pre-counseling Education for Low Literacy Women at Risk of Hereditary Breast and Ovarian Cancer (HBOC): Patient Experiences Using the Cancer Risk Education Intervention Tool (CREdIT)
- Author
-
Joseph, Galen, Beattie, Mary S., Lee, Robin, Braithwaite, Dejana, Wilcox, Carolina, Metrikin, Maya, Lamvik, Kate, and Luce, Judith
- Subjects
Biomedicine ,Ethics ,Gynecology ,Human Genetics ,Clinical Psychology ,Public Health/Gesundheitswesen ,Hereditary breast and ovarian cancer ,Health disparities ,Underserved ,Genetic Education ,Qualitative Research - Abstract
The Cancer Risk Education Intervention Tool (CREdIT) is a computer-based (non-interactive) slide presentation designed to educate low-literacy, and ethnically and racially diverse public hospital patients at risk of Hereditary Breast and Ovarian Cancer (HBOC) about genetics. To qualitatively evaluate participants’ experience with and perceptions of a genetic education program as an adjunct to genetic counseling, we conducted direct observations of the intervention, semi-structured in person interviews with 11 women who viewed CREdIT, and post-counseling questionnaires with the two participating genetic counselors. Five themes emerged from the analysis of interviews: (1) genetic counseling and testing for breast/ovarian cancer was a new concept; (2) CREdIT’s story format was particularly appealing; (3) changes in participants’ perceived risk for breast cancer varied; (4) some misunderstandings about individual risk and heredity persisted after CREdIT and counseling; (5) the context for viewing CREdIT shaped responses to the presentation. Observations demonstrated ways to make the information provided in CREdIT and by genetic counselors more consistent. In a post-session counselor questionnaire, counselors’ rating of the patient’s preparedness before the session was significantly higher for patients who viewed CREdIT prior to their appointments than for other patients. This novel educational tool fills a gap in HBOC education by tailoring information to women of lower literacy and diverse ethnic/racial backgrounds. The tool was well received by interview participants and counselors alike. Further study is needed to examine the varied effects of CREdIT on risk perception. In addition, the implementation of CREdIT in diverse clinical settings and the cultural adaptation of CREdIT to specific populations reflect important areas for future work.
- Published
- 2010
122. Hereditary breast and ovarian cancer in Andalusian families: a genetic population study
- Author
-
Bella Pajares, Javier Porta, Jose María Porta, Cristina Fernández-de Sousa, Ignacio Moreno, Daniel Porta, Gema Durán, Tamara Vega, Inmaculada Ortiz, Carolina Muriel, Emilio Alba, and Antonia Márquez
- Subjects
Hereditary breast and ovarian cancer ,BRCA1/BRCA2 mutation ,Genetic counselling ,Recurrent mutation ,Andalusian population ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background The BRCA1/2 mutation profile varies in Spain according to the geographical area studied. The mutational profile of BRCA1/2 in families at risk for hereditary breast and ovarian cancer has not so far been reported in Andalusia (southern Spain). Methods We analysed BRCA1/2 germline mutations in 562 high-risk cases with breast and/or ovarian cancer from Andalusian families from 2010 to 2015. Results Among the 562 cases, 120 (21.4%) carried a germline pathogenic mutation in BRCA1/2; 50 in BRCA1 (41.7%) and 70 in BRCA2 (58.3%). We detected 67 distinct mutations (29 in BRCA1 and 38 in BRCA2), of which 3 in BRCA1 (c.845C > A, c.1222_1223delAC, c.2527delA) and 5 in BRCA2 (c.293 T > G, c.5558_5559delGT, c.6034delT, c.6650_6654delAAGAT, c.6652delG) had not been previously described. The most frequent mutations in BRCA1 were c.5078_5080delCTG (10%) and c.5123C > A (10%), and in BRCA2 they were c.9018C > A (14%) and c.5720_5723delCTCT (8%). We identified 5 variants of unknown significance (VUS), all in BRCA2 (c.5836 T > C, c.6323G > T, c.9501 + 3A > T, c.8022_8030delGATAATGGA, c.10186A > C). We detected 76 polymorphisms (31 in BRCA1, 45 in BRCA2) not associated with breast cancer risk. Conclusions This is the first study reporting the mutational profile of BRCA1/2 in Andalusia. We identified 21.4% of patients harbouring BRCA1/2 mutations, 58.3% of them in BRCA2. We also characterized the clinical data, mutational profile, VUS and haplotype profile.
- Published
- 2018
- Full Text
- View/download PDF
123. MEDICAL AND GENETIC COUNSELING OF HEREDITARY BREAST AND OVARIAN CANCER
- Author
-
S. A. Laptiev, M. A. Korzhenevskaia, A. P. Sokolenko, A. G. Iyevleva, and E. N. Imyanitov
- Subjects
familial cancer ,hereditary breast and ovarian cancer ,genes brca 1/2 ,medical and genetic counseling ,preventive care ,Medicine (General) ,R5-920 - Abstract
Hereditary breast and ovarian cancer is one of the most common genetic pathology. Medical and genetic counseling of patients with hereditary breast and ovarian cancer and their families plays the important role in cancer care, as it helps to develop the set of diagnostic, preventive and therapeutic measures aimed at monitoring healthy individuals and to create personalized approaches to the treatment of patients.
- Published
- 2018
- Full Text
- View/download PDF
124. Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history
- Author
-
Christoph Engel, Kerstin Rhiem, Eric Hahnen, Sibylle Loibl, Karsten E. Weber, Sabine Seiler, Silke Zachariae, Jan Hauke, Barbara Wappenschmidt, Anke Waha, Britta Blümcke, Marion Kiechle, Alfons Meindl, Dieter Niederacher, Claus R. Bartram, Dorothee Speiser, Brigitte Schlegelberger, Norbert Arnold, Peter Wieacker, Elena Leinert, Andrea Gehrig, Susanne Briest, Karin Kast, Olaf Riess, Günter Emons, Bernhard H. F. Weber, Jutta Engel, Rita K. Schmutzler, and on behalf of the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC)
- Subjects
Hereditary breast and ovarian cancer ,BRCA1 ,BRCA2 ,Triple-negative breast cancer ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background There is no international consensus up to which age women with a diagnosis of triple-negative breast cancer (TNBC) and no family history of breast or ovarian cancer should be offered genetic testing for germline BRCA1 and BRCA2 (gBRCA) mutations. Here, we explored the association of age at TNBC diagnosis with the prevalence of pathogenic gBRCA mutations in this patient group. Methods The study comprised 802 women (median age 40 years, range 19–76) with oestrogen receptor, progesterone receptor, and human epidermal growth factor receptor type 2 negative breast cancers, who had no relatives with breast or ovarian cancer. All women were tested for pathogenic gBRCA mutations. Logistic regression analysis was used to explore the association between age at TNBC diagnosis and the presence of a pathogenic gBRCA mutation. Results A total of 127 women with TNBC (15.8%) were gBRCA mutation carriers (BRCA1: n = 118, 14.7%; BRCA2: n = 9, 1.1%). The mutation prevalence was 32.9% in the age group 20–29 years compared to 6.9% in the age group 60–69 years. Logistic regression analysis revealed a significant increase of mutation frequency with decreasing age at diagnosis (odds ratio 1.87 per 10 year decrease, 95%CI 1.50–2.32, p 10% for women diagnosed below approximately 50 years. Conclusions Based on the general understanding that a heterozygous mutation probability of 10% or greater justifies gBRCA mutation screening, women with TNBC diagnosed before the age of 50 years and no familial history of breast and ovarian cancer should be tested for gBRCA mutations. In Germany, this would concern approximately 880 women with newly diagnosed TNBC per year, of whom approximately 150 are expected to be identified as carriers of a pathogenic gBRCA mutation.
- Published
- 2018
- Full Text
- View/download PDF
125. Impact of a Structured Early Detection Program on Adherence to Guidelines for Risk-Reducing Surgery in BRCA1/2 Carriers.
- Author
-
Guo, Xiaoyue M., Cowan, Matthew, Pyrzak, Adam, Shulman, Lee, and Barber, Emma L.
- Subjects
- *
CONFIDENCE intervals , *GENETIC counseling , *LONGITUDINAL method , *MEDICAL protocols , *GENETIC mutation , *BRCA genes , *EARLY detection of cancer , *ODDS ratio , *HYSTERO-oophorectomy - Abstract
Objective: To determine the proportion of women with BRCA1/BRCA2 mutations participating in an ovarian cancer screening program who adhere to National Comprehensive Cancer Network (NCCN) guidelines for risk-reducing bilateral salpingo-oophorectomy (BRCA1 = 40 years, BRCA2 = 45 years). Design: Retrospective cohort study. Materials and Methods: Records were reviewed of all patients with BRCA1/BRCA2 mutations who were screened in Northwestern University's Ovarian Cancer Early Detection and Protection Program from 2002 to 2016. Exclusion criteria included a prior ovarian cancer diagnosis, oophorectomy before screening, or if visits were not recorded in the prospectively collected database. The primary endpoint was age at ovarian removal. Results: Of 134 patients identified (BRCA1, n = 83; BRCA2, n = 51), 46 patients underwent risk-reducing salpingo-oophorectomy (RRSO). Most surgeries (38/46, 83%) were performed by the upper limit of the mutation-specific recommended age. Of the 86 patients who have not undergone surgery, 49 patients are not yet at the recommended age for RRSO, 4 chose to continue screening, and 33 transferred care or were lost to follow-up. Patients were more likely to have prophylactic surgery by guideline-recommended age if they identified racially as white compared with non-white (odds ratio 7.5, 95% confidence interval 1.5–36.2, p = 0.02). Conclusion: More than 80% of BRCA patients in our program who obtained RRSO did so by the NCCN recommended ages. Indeed, most patients with BRCA1/BRCA2 who have not undergone surgery are still participating in the program. As more malignancy-related genes are discovered and evolving technologies developed for both genetic testing and cancer detection, screening programs may yet find a place in the management of high-risk patients. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
126. Screening of BRCA1/2 genes mutations and copy number variations in patients with high risk for hereditary breast and ovarian cancer syndrome (HBOC).
- Author
-
El Ansari, Fatima Zahra, Jouali, Farah, Marchoudi, Nabila, Bennani, Mohcine Mechita, Ghailani, Naima Nourouti, Barakat, Amina, and Fekkak, Jamal
- Subjects
- *
HEREDITARY cancer syndromes , *GENETIC mutation , *OVARIAN cancer , *BREAST cancer , *NANOTECHNOLOGY , *DNA copy number variations - Abstract
Background: Hereditary breast and ovarian cancer (HBOC) is an autosomal dominant inherited cancer susceptibility disorder. Both BRCA1 and BRCA2 genes are considered as high penetrance genes of this syndrome. The identification of BRCA1/2 genetic alterations before cancer development, grant patients the chance to benefit from various medical cancer prevention approaches. Therefore, the appearance of recent advanced technologies in molecular analysis such as next generation sequencing has simplified full BRCA1/2 analysis. Many attempts took place in hope of understanding the molecular germline spectrum of these two genes in Moroccan HBOC patients. However, most of the past projects focused only on young breast cancer cases, lacked ovarian cancer cases in their cohort and only a limited number of these studies were able to analyze the entire exons or copy number variations for both genes. In attempt of gaining more information regarding the molecular profile of BRCA1/2 in HBOC, we conducted a study in which we analyze their molecular profile on selected Moroccan patients suspected of having HBOC syndrome.Methods: In this study we obtained blood samples from 64 selected Moroccan patients, who suffered from Breast and/or ovarian cancer and had a strong family history for cancer. To analyze BRCA1/2 punctual variants and copy number variations, we used the Ion Personal Genome Machine (PGM) and Oncomine BRCA1/2 research assay panel. Afterward, we correlated the molecular results with the clinic-pathologic data using IBM SPSS Statistics ver 2.Results: From the 64 selected cases, Forty-six had breast cancer, fifteen had ovarian cancer and three had both breast and ovarian cancer. The molecular analysis revealed that 18 patients from the 64 harbored a pathogenic variant (28%). Twelve had six different BRCA1 pathogenic variants and six had six different BRCA2 pathogenic variants. In this study, we report four pathogenic variants that to the best of our knowledge has never been reported in the Moroccan population before. Regarding copy number variation analysis, No CNV was detected in both genes for all the 64 successfully sequenced and analyzed patients in our cohort.Conclusion: Work like the present has an important implication on public health and science. It is critical that molecular profiling studies are performed on underserved and understudied population like Morocco. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
127. Reducing Disparities in Receipt of Genetic Counseling for Underserved Women at Risk of Hereditary Breast and Ovarian Cancer.
- Author
-
Sutton, Arnethea L., Hurtado-de-Mendoza, Alejandra, Quillin, John, Rubinsak, Lisa, Temkin, Sarah M., Gal, Tamas, and Sheppard, Vanessa B.
- Subjects
- *
ACADEMIC medical centers , *CANCER genetics , *CHI-squared test , *CONFIDENCE intervals , *EMPLOYMENT , *GENETIC counseling , *HEALTH services accessibility , *HEALTH status indicators , *HEALTH insurance , *MARITAL status , *MEDICAL care use , *MEDICAL referrals , *METROPOLITAN areas , *MULTIVARIATE analysis , *RACISM , *LOGISTIC regression analysis , *ELECTRONIC health records , *DESCRIPTIVE statistics , *ODDS ratio , *DISEASE risk factors - Abstract
Purpose: Genetic counseling (GC) provides critical risk prediction information to women at-risk of carrying a genetic alternation; yet racial/ethnic and socioeconomic disparities persist with regard to GC uptake. This study examined patterns of GC uptake after a referral in a racially diverse population. Materials and Methods: In an urban academic medical center, medical records were reviewed between January 2016 and December 2017 for women who were referred to a genetic counselor for hereditary breast and ovarian cancer. Study outcomes were making an appointment (yes/no) and keeping an appointment. We assessed sociodemographic factors and clinical factors. Associations between factors and the outcomes were analyzed using chi square, and logistic regression was used for multivariable analysis. Results: A total of 510 women were referred to GC and most made appointments. More than half were white (55.3%) and employed (53.1%). No significant associations were observed between sociodemographic factors and making an appointment. A total of 425 women made an appointment and 268 kept their appointment. Insurance status ( p = 0.003), marital status ( p = 0.000), and work status ( p = 0.039) were associated with receiving GC. In the logistic model, being married (odds ratio [OR] 2.119 [95% confidence interval, CI 1.341–3.347] p = 0.001) and having insurance (OR 2.203 [95% CI 1.208–4.016] p = 0.021) increased the likelihood of receiving counseling. Conclusions: Racial disparities in GC uptake were not observed in this sample. Unmarried women may need additional support to obtain GC. Financial assistance or other options need to be discussed during navigation as a way to lessen the disparity between women with insurance and those without. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
128. Double Heterozygosity in the BRCA1/2 Genes in a Turkish Patient with Bilateral Breast Cancer: A Case Report.
- Author
-
Duzkale, Neslihan and Eyerci, Nilnur
- Subjects
- *
BRCA genes , *TUMOR suppressor genes , *BREAST cancer , *HETEROZYGOSITY , *GENETIC variation , *OVARIAN cancer - Abstract
BRCA1 and BRCA2 tumor suppressor genes are responsible for a quarter of hereditary breast cancers. Double heterozygous (DH) pathogenic variant carrier status in these genes is an extremely rare condition, especially in non-Askenazi individuals. We report a woman patient with bilateral breast cancer that carries DH disease-causing variants in BRCA1/2 genes. The 45-year-old patient who was followed up with the diagnosis of metachronous bilateral breast cancer was diagnosed with cancer at the age of 39 and 43, respectively. BRCA1/2 genes of the patient were evaluated using Next-Generation Sequencing. In the patient, the c.2800C>T (p.Gln934Ter) pathogenic variant in BRCA1 and the c.9648+1G>C likely pathogenic variant in BRCA2 were detected as DH. Segregation analysis in family members revealed that her two healthy siblings available for testing were heterozygous for either BRCA1 or BRCA2 variants, but her mother, who had a past diagnosis of ovarian cancer, was heterozygous for both BRCA1 and BRCA2 variants. Germline double heterozygosity in inherited cancer is a rare condition, and as far as we know it is reported for the first time from patient population in Turkey. Large-scale patient series are needed to determine the impact of double heterozygosity on diseases course, such as prognosis and treatment responses. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
129. Implementing Cancer Genomics in State Health Agencies: Mapping Activities to an Implementation Science Outcome Framework.
- Author
-
Green, Ridgely Fisk, Kumerow, Marie T., Rodriguez, Juan L., Addie, Siobhan, Beachy, Sarah H., and Senier, Laura
- Subjects
- *
GOVERNMENT agencies , *HEREDITARY nonpolyposis colorectal cancer , *GENOMICS , *OVARIAN cancer , *CANCER prevention - Abstract
Objective: To show how state health agencies can plan and evaluate activities to strengthen the evidence base for public health genomics, we mapped state cancer genomics activities to the Doyle et al. [Genet Med. 2018;20(9):995–1003] implementation science outcome framework. Methods: We identified state health agency activities addressing hereditary breast and ovarian cancer and Lynch syndrome by reviewing project narratives from Centers for Disease Control and Prevention Cancer Genomics Program funding recipients, leading discussions with state health agencies, and conducting an environmental scan. Results: State health agencies' cancer genomics activities included developing or adding to state surveillance systems, developing educational materials, bidirectional reporting, promoting health plan policy change, training providers, and promoting recommendations and standards. To address health disparities, programs have tracked group differences, developed culturally appropriate educational materials, and promoted access to services for underserved populations. Conclusion: State health agencies can use the Doyle et al. [Genet Med. 2018;20(9):995–1003] performance objectives and outcome measures to evaluate proposed and ongoing activities. By demonstrating whether activities result in improved outcomes, state health agencies can build the evidence for the implementation of cancer genomics activities. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
130. Genetic cancer risk assessment: A screenshot of the psychosocial profile of women at risk for hereditary breast and ovarian cancer syndrome.
- Author
-
Campacci, Natalia, Campos Reis Galvão, Henrique, Garcia, Lucas F., Ribeiro, Paula C., Grasel, Rebeca S., Goldim, José R., Ashton‐Prolla, Patrícia, Palmero, Edenir I., de Campos Reis Galvão, Henrique, and Ashton-Prolla, Patrícia
- Subjects
- *
ADAPTABILITY (Personality) , *RESEARCH , *SOCIAL support , *CROSS-sectional method , *RESEARCH methodology , *GENETIC testing , *EVALUATION research , *MEDICAL cooperation , *RISK assessment , *COMPARATIVE studies , *RESEARCH funding , *CANCER genetics - Abstract
Objective: There is a lack of information describing Brazilian women at risk of hereditary breast and ovarian cancer syndrome (HBOC) who undergo genetic cancer risk assessment (GCRA). This study aims to characterize the psychosocial profile of women at risk for HBOC at their first GCRA to obtain an overview of their families' profiles and the challenges of the oncogenetics setting.Methods: This was a cross-sectional study in which interviews were conducted with 83 cancer-affected women at their first GRCA appointment after the pedigree draw. Tools to evaluate psychological outcomes were applied. The pedigree genogram and ecomap were constructed and analyzed with content analysis using the "life course perspective" theory.Results: Individuals perceived their breast/ovarian cancer risk to be equal to that of the general population, although they were highly concerned about developing cancer. No evidence of anxiety or depressive symptoms was identified. Participants used the coping strategy of searching for religiosity. The genograms and ecomaps resulted in five major themes: support and social support; attitudes, feelings and emotions; cancer causes; communication; and relationships with relatives. Individuals between 20-29 years of age and those with no family history of cancer tended not to communicate with relatives, which may indicate future problems in the GCRA process regarding genetic testing.Conclusions: This study demonstrated that knowing the families who undergo the GCRA process can help professionals provide more individualized and thorough attention during GCRA and genetic testing, which results in better follow-up and prevention strategies. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
131. How to facilitate psychosocial adjustment in women tested for hereditary breast or ovarian cancer susceptibility? Insights from network analysis.
- Author
-
Brédart, Anne, Dick, Julia, Cano, Alejandra, Robieux, Léonore, De Pauw, Antoine, Schmutzler, Rita, Stoppa‐Lyonnet, Dominique, Dolbeault, Sylvie, Kop, Jean‐Luc, Stoppa-Lyonnet, Dominique, and Kop, Jean-Luc
- Abstract
Background: Increasingly complex genetics counseling requires guidance to facilitate counselees' psychosocial adjustment. We explored networks of inter-relationships among coping strategies and specific psychosocial difficulties in women tested for hereditary breast or ovarian cancer.Methods: Of 752 counselees consecutively approached, 646 (86%) completed questionnaires addressing coping strategies (Brief-COPE) and psychosocial difficulties (PAHC) after the initial genetic consultation (T1), and 460 (61%) of them again after the test result (T2). We applied network analysis comparing partial correlations among these questionnaire scales, according to the type of genetic test - single gene-targeted or multigene panel, test result and, before and after testing.Results: Overall, 98 (21.3%), 259 (56.3%), 59 (12.8%) and 44 (9.6%) women received a pathogenic variant, uninformative negative (panel testing), variant of uncertain significance (VUS) or true negative (targeted testing) result, respectively. In most networks, connections were strongest between avoidance and general negative emotions. Cognitive restructuring was inter-related to lower psychosocial difficulties. Avoidance and familial/social relationship difficulties were strongly related in women receiving a pathogenic variant. Stronger inter-relationships were also noticed between avoidance and worries about personal cancer and concerns about hereditary predisposition in women receiving a VUS result. Differences in the prominence of inter-relationships were observed by type of testing and assessment time.Conclusions: Network analysis may be fruitful to highlight prominent inter-relationships among coping strategies and psychosocial difficulties, in women tested for HBOC susceptibility, offering guidance for counseling. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
132. Breast cancer risk in BRCA1/2 mutation carriers and noncarriers under prospective intensified surveillance.
- Author
-
Engel, Christoph, Fischer, Christine, Zachariae, Silke, Bucksch, Karolin, Rhiem, Kerstin, Giesecke, Jutta, Herold, Natalie, Wappenschmidt, Barbara, Hübbel, Verena, Maringa, Monika, Reichstein‐Gnielinski, Simone, Hahnen, Eric, Bartram, Claus R., Dikow, Nicola, Schott, Sarah, Speiser, Dorothee, Horn, Denise, Fallenberg, Eva M., Kiechle, Marion, and Quante, Anne S.
- Subjects
BREAST cancer ,BREAST imaging ,OVARIAN cancer ,HORMONE receptor positive breast cancer ,FILAGGRIN - Abstract
Comparably little is known about breast cancer (BC) risks in women from families tested negative for BRCA1/2 mutations despite an indicative family history, as opposed to BRCA1/2 mutation carriers. We determined the age‐dependent risks of first and contralateral breast cancer (FBC, CBC) both in noncarriers and carriers of BRCA1/2 mutations, who participated in an intensified breast imaging surveillance program. The study was conducted between January 1, 2005, and September 30, 2017, at 12 university centers of the German Consortium for Hereditary Breast and Ovarian Cancer. Two cohorts were prospectively followed up for incident FBC (n = 4,380; 16,398 person‐years [PY], median baseline age: 39 years) and CBC (n = 2,993; 10,090 PY, median baseline age: 42 years). Cumulative FBC risk at age 60 was 61.8% (95% CI 52.8–70.9%) for BRCA1 mutation carriers, 43.2% (95% CI 32.1–56.3%) for BRCA2 mutation carriers and 15.7% (95% CI 11.9–20.4%) for noncarriers. FBC risks were significantly higher than in the general population, with incidence rate ratios of 23.9 (95% CI 18.9–29.8) for BRCA1 mutation carriers, 13.5 (95% CI 9.2–19.1) for BRCA2 mutation carriers and 4.9 (95% CI 3.8–6.3) for BRCA1/2 noncarriers. Cumulative CBC risk 10 years after FBC was 25.1% (95% CI 19.6–31.9%) for BRCA1 mutation carriers, 6.6% (95% CI 3.4–12.5%) for BRCA2 mutation carriers and 3.6% (95% CI 2.2–5.7%) for noncarriers. CBC risk in noncarriers was similar to women with unilateral BC from the general population. Further studies are needed to confirm whether less intensified surveillance is justified in women from BRCA1/2 negative families with elevated risk. What's new? Women with a family history of breast cancer often have relatives who test negative for pathogenic BRCA1/2 mutations. Compared to BRCA1/2‐positive women, however, little is known about breast cancer risk among women from BRCA1/2‐negative families. In this study of women with and without BRCA1/2 mutations who participated in a German breast imaging surveillance program between 2005 and 2017, risk of first breast cancer was markedly lower in BRCA1/2‐negative women compared to BRCA1/2 mutation carriers. Relative to the general population, unilateral breast cancer risk was elevated in BRCA1/2‐negative women, while contralateral breast cancer risk was similar between the two groups. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
133. Identification of germline pathogenic variants in DNA damage repair genes by a next-generation sequencing multigene panel in BRCAX patients.
- Author
-
Rodríguez-Balada, Marta, Roig, Bàrbara, Melé, Mireia, Albacar, Cinta, Serrano, Sara, Salvat, Mònica, Querol, Montserrat, Borràs, Joan, Martorell, Lourdes, and Gumà, Josep
- Subjects
- *
DNA mismatch repair , *DNA repair , *NUCLEOTIDE sequencing , *DNA damage , *BRCA genes , *GENETIC testing - Abstract
• An 8% of diagnostic yield was obtained in the analysis of a 25 genes-panel. • Multigene panel should be included as a diagnostic tool in genetic testing. • PALB2 has to be included on Hereditary Breast and ovarian cancer testing. Approximately 5–10% of breast carcinomas have been related to hereditary conditions and are attributable to pathogenic variants in the BRCA1 and BRCA2 genes, which is referred to as hereditary breast and ovarian cancer (HBOC) syndrome. The inclusion of additional genes that can be related to HBOC syndrome is under intense evaluation due to the high proportion of patients with HBOC criteria who do not present pathogenic mutations in BRCA genes, named BRCAX, despite having high clinical suspicion of hereditary cancer. The main aim is to identify new potentially pathogenic gene variants that may contribute to HBOC to improve the efficiency of routine diagnostic tests in this hereditary condition. A retrospective cohort of 77 HBOC BRCAX patients was analyzed by next-generation sequencing using a targeted multigene panel composed of 25 genes related to hereditary cancer and deficiencies in DNA repair pathways. We found 9 variants in 7 different genes, which were confirmed by automated sequencing. Six variants were classified as pathogenic or likely pathogenic. Three of them were located in the PALB2 gene, one in the BRIP1 gene, one in the BARD1 gene and 1 in the RAD50 gene. In addition, three variants of uncertain significance (VUS) were detected in the TP53, CHEK2, and CDH1 genes. We identified that 8% of BRCAX patients were carriers of pathogenic variants in genes other than BRCA1 and BRCA2. Therefore, wide gene panels, including clinically actionable genes, should be routinely used in the screening of HBOC in our population. We observed differences from other studies in the prevalence of mutated genes, most likely due to differences in the selection criteria of the probands and in the population analyzed. The high incidence of deleterious variant detection in PALB2 supports its significant role in breast cancer susceptibility and reinforces its inclusion in the HBOC genetic diagnostic process. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
134. Illustrating Cancer Risk: Patient Risk Communication Preferences and Interest regarding a Novel BRCA1/2 Genetic Risk Modifier Test.
- Author
-
Hamilton, Jada G., Genoff Garzon, Margaux, Shah, Ibrahim H., Cadet, Kechna, Shuk, Elyse, Westerman, Joy S., Hay, Jennifer L., Offit, Kenneth, and Robson, Mark E.
- Subjects
- *
RISK communication , *CANCER patients , *GENETIC testing , *SINGLE nucleotide polymorphisms ,CANCER susceptibility - Abstract
Introduction: Genetic risk modifier testing (GRMT), an emerging form of genetic testing based on common single nucleotide polymorphisms and polygenic risk scores, has the potential to refine estimates of BRCA1/2 mutation carriers' breast cancer risks. However, for women to benefit from GRMT, effective approaches for communicating this novel risk information are needed. Objective: To evaluate patient preferences regarding risk communication materials for GRMT. Methods: We developed four separate presentations (panel of genes, icon array, verbal risk estimate, graphical risk estimate) of hypothetical GRMT results, each using varying risk communication strategies to convey different information elements including number of risk modifier variants present, variant prevalence among BRCA1/2 carriers, and implications and uncertainties of test results for cancer risk. Thirty BRCA1/2 carriers evaluated these materials (randomized to low, moderate, or high breast cancer risk versions). Qualitative and quantitative data were obtained through in-person interviews. Results: Across risk versions, participants preferred the presentation of the graphical risk estimate, often in combination with the verbal risk estimate. Interest in GRMT was high; 76.7% of participants wanted their own GRMT. Participants valued the potential for GRMT to clarify their cancer susceptibility and provide actionable information. Many (65.5%) anticipated that GRMT would make risk management decisions easier. Conclusions: Women with BRCA1/2 mutations could be highly receptive to GRMT, and the minimal amount of necessary information to be included in result risk communication materials includes graphical and verbal estimates of future cancer risk. Findings will inform clinical translation of GRMT in a manner consistent with patients' preferences. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
135. Developing a culturally targeted video to enhance the use of genetic counseling in Latina women at increased risk for hereditary breast and ovarian cancer.
- Author
-
Hurtado-de-Mendoza, Alejandra, Graves, Kristi D., Gómez-Trillos, Sara, Song, Minna, Anderson, Lyndsay, Campos, Claudia, Carrera, Pilar, Ostrove, Nancy, Peshkin, Beth N., Schwartz, Marc D., Ficca, Nan, Cupertino, Ana-Paula, Gonzalez, Nathaly, Otero, Andrea, Huerta, Elmer, and Sheppard, Vanessa B.
- Abstract
Disparities for genetic cancer risk assessment (GCRA) for hereditary breast and ovarian cancer (HBOC) persist between Latina and non-Hispanic Whites. There are few tested culturally targeted interventions. We developed a culturally targeted video to enhance GCRA uptake in at-risk Latinas. Interviews with healthcare providers (n = 20) and at-risk Latinas (n = 20) were conducted as formative research to inform the development of the video. Findings from the formative research, health behavior conceptual models, and evidence-based risk communication strategies informed the messages for the script. Then, we conducted a focus group with at-risk Latinas (n = 7) to obtain feedback for final refinement of the script. The final video was piloted for acceptability and potential dissemination in a sample of Latino community health workers (CHWs) (n = 31). Providers and at-risk Latinas suggested using simple language and visual aids to facilitate comprehension. Participants in the focus group identified areas for further clarification (e.g., cost). The result was an 18-min video that illustrates "Rosa's" story. Rosa learns about HBOC risk factors and overcomes barriers to attend genetic counseling. CHWs reported high overall satisfaction with the video (M = 9.61, SD =.88, range 1–10). A culturally targeted video has the potential to reach underserved populations with low literacy and English proficiency. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
136. Germline variant of BRCA1 c.5332G>A has clinical features of hereditary breast and ovarian cancer syndrome
- Author
-
Saita, Chiaki, Aruga, Tomoyuki, Adachi, Mio, Kumaki, Yuichi, Iwamoto, Naoko, Yonekura, Rika, Nakatsugawa, Noriko, Inokuchi, Takuhiko, Ishiba, Toshiyuki, Honda, Yayoi, and Yamaguchi, Tatsuro
- Published
- 2022
- Full Text
- View/download PDF
137. Predictive Genetic Testing
- Author
-
Minor, Jessica and Minor, Jessica
- Published
- 2015
- Full Text
- View/download PDF
138. Detection of Germline Variants in 450 Breast/Ovarian Cancer Families with a Multi-Gene Panel Including Coding and Regulatory Regions
- Author
-
Chiara Guglielmi, Rosa Scarpitta, Gaetana Gambino, Eleonora Conti, Francesca Bellè, Mariella Tancredi, Tiziana Cervelli, Elisabetta Falaschi, Cinzia Cosini, Paolo Aretini, Caterina Congregati, Marco Marino, Margherita Patruno, Brunella Pilato, Francesca Spina, Luisa Balestrino, Elena Tenedini, Ileana Carnevali, Laura Cortesi, Enrico Tagliafico, Maria Grazia Tibiletti, Stefania Tommasi, Matteo Ghilli, Caterina Vivanet, Alvaro Galli, and Maria Adelaide Caligo
- Subjects
hereditary breast and ovarian cancer ,BRCA1/2 ,breast cancer predisposition genes ,coding variants ,non-coding variants ,regulatory regions ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
With the progress of sequencing technologies, an ever-increasing number of variants of unknown functional and clinical significance (VUS) have been identified in both coding and non-coding regions of the main Breast Cancer (BC) predisposition genes. The aim of this study is to identify a mutational profile of coding and intron-exon junction regions of 12 moderate penetrance genes (ATM, BRIP1, CDH1, CHEK2, NBN, PALB2, PTEN, RAD50, RAD51C, RAD51D, STK11, TP53) in a cohort of 450 Italian patients with Hereditary Breast/Ovarian Cancer Syndrome, wild type for germline mutation in BRCA1/2 genes. The analysis was extended to 5′UTR and 3′UTR of all the genes listed above and to the BRCA1 and BRCA2 known regulatory regions in a subset of 120 patients. The screening was performed through NGS target resequencing on the Illumina platform MiSeq. 8.7% of the patients analyzed is carriers of class 5/4 coding variants in the ATM (3.6%), BRIP1 (1.6%), CHEK2 (1.8%), PALB2 (0.7%), RAD51C (0.4%), RAD51D (0.4%), and TP53 (0.2%) genes, while variants of uncertain pathological significance (VUSs)/class 3 were identified in 9.1% of the samples. In intron-exon junctions and in regulatory regions, variants were detected respectively in 5.1% and in 32.5% of the cases analyzed. The average age of disease onset of 44.4 in non-coding variant carriers is absolutely similar to the average age of disease onset in coding variant carriers for each proband’s group with the same cancer type. Furthermore, there is not a statistically significant difference in the proportion of cases with a tumor onset under age of 40 between the two groups, but the presence of multiple non-coding variants in the same patient may affect the aggressiveness of the tumor and it is worth underlining that 25% of patients with an aggressive tumor are carriers of a PTEN 3′UTR-variant. This data provides initial information on how important it might be to extend mutational screening to the regulatory regions in clinical practice.
- Published
- 2021
- Full Text
- View/download PDF
139. Prophylactic Interventions for Hereditary Breast and Ovarian Cancer Risks and Mortality in BRCA1/2 Carriers.
- Author
-
Liu T, Yu J, Gao Y, Ma X, Jiang S, Gu Y, and Ming WK
- Abstract
Background: Hereditary breast and ovarian cancers (HBOCs) pose significant health risks worldwide and are mitigated by prophylactic interventions. However, a meta-analysis of their efficacy and the impact of different genetic variants on their effectiveness is lacking., Methods: A systematic review and meta-analysis were conducted, adhering to Cochrane guidelines. The review encompassed studies that involved prophylactic interventions for healthy women with BRCA variants, focusing on cancer incidence and mortality outcomes. The Newcastle-Ottawa Scale was used for risk of bias assessment. We pooled the extracted outcomes using random effects models and conducted subgroup analyses stratified by intervention, variant, and cancer types., Results: A total of 21 studies met the inclusion criteria. The meta-analysis revealed that prophylactic interventions significantly reduced cancer risk and mortality. The subgroup analysis showed a greater protective effect for BRCA2 than BRCA1 variant carriers. Risk-reducing surgeries (RRS) were more effective than chemoprevention, with RRS notably reducing cancer risk by 56% compared to 39% for chemoprevention. Prophylactic oophorectomy significantly reduced HBOC risks, while the effect of prophylactic mastectomy and chemoprevention on mortality was less conclusive., Conclusions: Prophylactic interventions significantly reduce the risk of HBOC and associated mortality. This comprehensive analysis provides insights for future economic evaluations and clinical decision-making in HBOC interventions.
- Published
- 2023
- Full Text
- View/download PDF
140. UNCERTAINTY IN HEREDITARY CANCER RISK MANAGEMENT.
- Subjects
OVARIAN cancer ,BREAST cancer ,DECISION making ,HEALTH risk assessment ,BRCA genes ,CANCER in women ,GENETIC disorders ,EARLY detection of cancer - Abstract
This study explores the uncertainties of previvors--women who test positive for a harmful BRCA genetic mutation, which greatly increases their lifetime risk for developing hereditary breast and ovarian cancer (HBOC)--and the health decisions they make to manage their uncertainties. Framed by Mishel's reconceptualized uncertainty in illness theory (RUIT), this study demonstrates that previvors experience uncertainty regarding the possibility of a future cancer diagnosis and the choices about cancer risk management. When contemplating health decisions to manage their HBOC risk, previvors assessed uncertainty about a future cancer diagnosis as both a danger and an opportunity, with previvors who appraised their cancer risk as a danger undergoing preventive surgeries and previvors who appraised their cancer risk as an opportunity choosing increased surveillance. Implications for cancer risk management decisionmaking and patient-provider interactions about genetic cancer risk are discussed. [ABSTRACT FROM AUTHOR]
- Published
- 2018
141. Uncertainty and previvors' cancer risk management: understanding the decision-making process.
- Author
-
Dean, Marleah and Fisher, Carla L.
- Subjects
- *
GENETIC mutation , *MEDICAL decision making , *OVARIAN cancer , *DISEASE risk factors , *GENETIC testing - Abstract
Women who test positive for a BRCA genetic mutation, but who have not been diagnosed, or 'previvors,' experience intense, chronological risk-related uncertainty. Women's risk management medical decisions can be a way to manage their uncertainty, but little is known about how uncertainty informs their decision or how uncertainty is impacted by these medical decisions. Using an uncertainty management theoretical lens, we interviewed 46 previvors about their decision-making process. A thematic analysis revealed two uncertainty management (i.e., risk-reducing) decision-making pathways (preventive surgery and increased surveillance) with each pathway encompassing a three-part process of 1) uncertainty appraisal, 2) medical decision (i.e., uncertainty management strategy), and 3) outcomes. The findings advance theoretical thinking about uncertainty and risk management as an ongoing, distressful chronic experience, and highlight the importance of life-span phenomena in women's decision-making process. Based on the findings, we constructed a translational tool to aid genetic counselors and previvors facing these medical decisions. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
142. Barriers to the utilization of genetic testing and genetic counseling in patients with suspected hereditary breast and ovarian cancers.
- Author
-
Swink, Alicia, Nair, Anju, Hoof, Pamela, Matthews, Antoinette, Burden, Chelsey, Johnson, Kelly, and Blum, Joanne L.
- Abstract
A heritable condition is the identified cause of cancer in 5% to 10% of women with breast cancer and in 25% of women with ovarian cancer. It is critical to identify patients at risk for inherited genetic mutations to implement risk-reducing screening and interventions; however, reports in the medical literature indicate that an alarming number of patients with inherited genetic mutations do not receive recommended genetic counseling, testing, or interventions. In order to improve outcomes for these high-risk patients, barriers to genetic testing and counseling must be identified. We analyzed approximately 200 patients seen at our institution with breast or ovarian cancer who met criteria of the National Comprehensive Cancer Network for genetic counseling and testing. Of these patients, almost 70% had appropriate genetic testing and counseling. Review of the remaining 30% revealed that the largest obstacle to receiving genetic testing and/or counseling was lack of referral from the treating oncologist. Of the patients diagnosed with a pathogenic heritable mutation, most underwent appropriate risk-reducing procedures and surveillance. Thus, the initial referral to genetic counseling is the most significant barrier for at-risk patients at our institution and likely in this population at large. Additional study is needed to identify ways to improve appropriate use of genetic testing and counseling. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
143. Uptake of genetic testing for germline BRCA1/2 pathogenic variants in a predominantly Hispanic population.
- Author
-
McGuinness, Julia E., Trivedi, Meghna S., Silverman, Thomas, Marte, Awilda, Mata, Jennie, Kukafka, Rita, and Crew, Katherine D.
- Subjects
- *
GENETIC testing , *GENETIC counseling , *ACADEMIC medical centers , *FAMILY history (Medicine) , *POPULATION - Abstract
Genetic counseling is under-utilized in women who meet family history criteria for BRCA1 and BRCA2 (BRCA1/2) testing, particularly among racial/ethnic minorities. We evaluated the uptake of BRCA1/2 genetic testing among women presenting for screening mammography in a predominantly Hispanic, low-income population of Washington Heights in New York City. We administered the Six-Point Scale (SPS) to women presenting for screening mammography at Columbia University Irving Medical Center (CUIMC) in the Washington Heights neighborhood of New York, NY. The SPS is a family history screener to determine eligibility for BRCA1/2 genetic testing based upon U.S. Preventive Services Task Force (USPSTF) guidelines that has been validated in low-income, multiethnic populations. Among women who underwent screening mammography at CUIMC between November 2014 and June 2016, 3,055 completed the SPS family history screener. Participants were predominantly Hispanic (76.7%), and 12% met family history criteria for BRCA1/2 testing, of whom <5% had previously undergone testing. In a multiethnic population, a significant proportion met family history criteria for BRCA1/2 testing, but uptake of genetic testing was low. Such underutilization of BRCA1/2 genetic testing among minorities further underscores the need to develop programs to engage high-risk women from underrepresented populations in genetic testing services. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
144. FANCM, RAD1, CHEK1 and TP53I3 act as BRCA-like tumor suppressors and are mutated in hereditary ovarian cancer.
- Author
-
Lopes, Jaime L., Chaudhry, Sophia, Lopes, Guilherme S., Levin, Nancy K., and Tainsky, Michael A.
- Subjects
- *
OVARIAN cancer , *TUMOR suppressor genes , *P53 antioncogene , *DNA damage , *TUMORS , *CELL survival - Abstract
• Deficiency of CHEK1, FANCM and TP53I3 led to reduced homologous recombination repair efficiency. • Deficiency of RAD1, CHEK1 or FANCM led to a decrease in cellular viability. • Deficiency of CHEK1, RAD1 or TP53I3 displayed increased sensitivity to cisplatin. • Deficiency of CHEK1, REC8 or RAD1 display increased sensitivity etoposide. • Results corroborate whole exome sequencing and bioinformatics analyses that identified FANCM, RAD1, CHEK1 and TP53I3 , as putative germline risk loci in inherited breast and ovarian cancer risk. Although 25% of ovarian cancer cases are due to inherited factors, most of the genetic risk remains unexplained. We previously identified candidate genes through germline whole exome sequencing of BRCA1/BRCA2 negative ovarian cancer patients with familial risk. Here, we performed functional assessment to determine whether they act as BRCA -like tumor suppressors. Seven candidate risk genes were targeted by siRNA for mRNA depletion followed by functional assays for clonogenic survival, cytotoxicity to DNA damaging agents, and involvement in homologous recombination repair. BRCA1 and BRCA1 were targeted as standards for loss of function outcome. Knockdown of various candidate genes led to tumor suppressor phenotypes also observed in BRCA1/BRCA2 deficient cells. Deficiency of CHEK1, FANCM and TP53I3 led to reduced homologous recombination repair efficiency. Knockdown of RAD1, CHEK1 or FANCM led to a decrease in cellular viability and cells deficient in CHEK1, RAD1 or TP53I3 displayed increased sensitivity to cisplatin. Functional studies of candidate genes identified by whole exome sequencing complements bioinformatics techniques and aid the implication of novel risk loci. The results of this study suggest that genes found mutated in hereditary ovarian cancer, FANCM, RAD1, CHEK1 and TP53I3 , act as BRCA- like tumor suppressors. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
145. The identification of pathogenic variants in BRCA1/2 negative, high risk, hereditary breast and/or ovarian cancer patients: High frequency of FANCM pathogenic variants.
- Author
-
Schubert, Stephanie, Luttikhuizen, Jana L., Auber, Bernd, Schmidt, Gunnar, Hofmann, Winfried, Penkert, Judith, Davenport, Colin F., Hille‐Betz, Ursula, Wendeburg, Lena, Bublitz, Janin, Tauscher, Marcel, Hackmann, Karl, Schröck, Evelin, Scholz, Caroline, Wallaschek, Hannah, Schlegelberger, Brigitte, Illig, Thomas, and Steinemann, Doris
- Abstract
NGS‐based multiple gene panel resequencing in combination with a high resolution CGH‐array was used to identify genetic risk factors for hereditary breast and/or ovarian cancer in 237 high risk patients who were previously tested negative for pathogenic BRCA1/2 variants. All patients were screened for pathogenic variants in 94 different cancer predisposing genes. We identified 32 pathogenic variants in 14 different genes (ATM, BLM, BRCA1, CDH1, CHEK2, FANCG, FANCM, FH, HRAS, PALB2, PMS2, PTEN, RAD51C and NBN) in 30 patients (12.7%). Two pathogenic BRCA1 variants that were previously undetected due to less comprehensive and sensitive methods were found. Five pathogenic variants are novel, three of which occur in genes yet unrelated to hereditary breast and/or ovarian cancer (FANCG, FH and HRAS). In our cohort we discovered a remarkably high frequency of truncating variants in FANCM (2.1%), which has recently been suggested as a susceptibility gene for hereditary breast cancer. Two patients of our cohort carried two different pathogenic variants each and 10 other patients in whom a pathogenic variant was confirmed also harbored a variant of unknown significance in a breast and ovarian cancer susceptibility gene. We were able to identify pathogenic variants predisposing for tumor formation in 12.3% of BRCA1/2 negative breast and/or ovarian cancer patients. What's new? Risk for hereditary breast and ovarian cancer (HBOC) is mainly determined by BRCA1/2 mutations but in ~60% of cases the genetic predisposition remains unknown. The authors screened more than 200 women with BRCA1/2‐negative HBOC for new pathogenic variants using a combination of multi‐gene panel sequencing and comparative genomic hybridization. A remarkably high frequency of truncating variants in FANCM were discovered, a protein recently suggested as a susceptibility gene for hereditary breast cancer. The authors recommend that combined methods be used to identify new variants for HBOC risk assessment. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
146. Multigene panel testing versus syndrome-specific germline testing for inherited cancer risk: 'a somewhat different way'.
- Author
-
Biller, Leah H and Yurgelun, Matthew B
- Published
- 2019
- Full Text
- View/download PDF
147. Selected medical interventions in women with a deleterious BRCA mutation: a population-based study in British Columbia.
- Author
-
Hanley, G. E., McAlpine, J. N., Cheifetz, R., Schrader, K. A., McCullum, M., and Huntsman, D.
- Subjects
- *
GYNECOLOGIC cancer , *BREAST cancer , *FALLOPIAN tubes , *OVARIAN cancer , *ORAL contraceptives , *HYSTERO-oophorectomy - Abstract
Background We examined the uptake of risk-reducing interventions, including bilateral mastectomy, risk-reducing salpingo-oophorectomy, oral contraceptive pills, tamoxifen, and raloxifene, for the entire population of women with a deleterious BRCA1 or BRCA2 mutation in the Canadian province of British Columbia. Methods This retrospective population-based study used data available in British Columbia for all women who, between 1996 and 2014, were tested and found to have a BRCA mutation. Rates of risk-reducing interventions stratified according to the type of BRCA mutation and prior history of breast or gynecologic cancer (ovary, fallopian tube, peritoneal) are presented. Cancers diagnosed in women with a BRCA mutation after disclosure of their mutation status are also presented. Results The final study cohort consisted of 885 patients with a deleterious BRCA1 (n = 474) or BRCA2 (n = 411) mutation. Of the women with no prior breast cancer, 30.8% carrying a BRCA1 mutation and 28.3% carrying a BRCA2 mutation underwent bilateral mastectomy. Of women with no prior gynecologic cancer, 64.7% carrying a BRCA1 mutation and 62.2% carrying a BRCA2 mutation underwent risk-reducing bilateral salpingo-oophorectomy. Rates of chemoprevention with oral contraceptive pills and tamoxifen or raloxifene were low in all groups. In this cohort, 23 gynecologic and 70 breast cancers were diagnosed after disclosure of BRCA mutation status. Conclusions Our results suggest reasonable uptake of risk-reducing interventions in high-risk women. To minimize the occurrence of breast and ovarian cancer in women with a BRCA1 or BRCA2 mutation, more attention could be paid to ensuring that affected women receive proper counselling and follow-up. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
148. Genetic Testing Across Young Hispanic and Non-Hispanic White Breast Cancer Survivors: Facilitators, Barriers, and Awareness of the Genetic Information Nondiscrimination Act.
- Author
-
Cragun, Deborah, Weidner, Anne, Kechik, Joy, and Pal, Tuya
- Subjects
- *
BREAST cancer , *CANCER patients , *GENETIC mutation , *CANCER cells , *CANCER treatment - Abstract
Aims: This study compared facilitators and barriers to genetic testing and determined awareness about the Genetic Information Nondiscrimination Act (GINA) across young Hispanic and non-Hispanic white (NHW) breast cancer (BC) survivors. Materials and Methods: Women diagnosed with BC of age ≤50 years in 2009–2012 were recruited through the Florida State Cancer Registry to complete a questionnaire. Results: There were 1182 participants of which 61% (174/285) of Hispanic patients, and 65% (580/897) of NHW patients had BC testing. Among untested participants, the most common barriers were lack of testing recommendation (44% Hispanics, 32% NHW; p = 0.02) and cost-related concerns (41% Hispanics, 40% NHW; p = 0.83). Among tested participants, the top facilitators were as follows: (1) "To benefit my family's future" (70% Hispanic, 68% NHW), (2) "My doctor recommended testing" (60% Hispanic, 54% NHW), and (3) "Minimal cost to me" (59% Hispanic, 72% NHW). Only 27% of tested and 15% of untested women were aware of GINA; misuse of test results was reported as a barrier for only 6.5%. Conclusions: Rates of genetic testing recommendation are lower among Hispanics, but both groups reported additional barriers. Most are unaware of GINA, yet misuse is not a highly cited barrier. Findings suggest the need to educate providers on the importance of recommending testing to all who meet criteria; increase awareness of newer options for more affordable testing; and bolster facilitators that may increase testing uptake. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
149. A PALB2 truncating mutation: Implication in cancer prevention and therapy of Hereditary Breast and Ovarian Cancer.
- Author
-
Velázquez, Carolina, Esteban-Cardeñosa, Eva M., Lastra, Enrique, Abella, Luis E., de la Cruz, Virginia, Lobatón, Carmen D., Durán, Mercedes, and Infante, Mar
- Subjects
BREAST cancer ,OVARIAN cancer ,GERM cells ,CANCER treatment ,PATIENT-family relations - Abstract
Abstract Explaining genetic predisposition in Hereditary Breast and Ovarian Cancer (HBOC) families without BRCA mutations is crucial. Germline PALB2 inactivating mutations were associated with an increased risk of HBOC due to its role in DNA repair through cooperation with BRCA proteins. The prevalence and penetrance of PALB2 mutations in Spanish HBOC patients remains unexplained. PALB2 mutation screening has been conducted in 160 high-risk BRCA-negative patients and 320 controls. We evaluated four predicted splicing disruption variants and large genomic rearrangements by multiplex ligation-dependent probe amplification. We have found a frameshift mutation which segregates in an early onset cancer family; and four rare missense variants. None of the variants tested for a predicted splicing disruption showed an aberrant transcript pattern. No large genomic rearrangements were detected. Although PALB2 truncating mutations are rarely identified, segregation analysis and early onset cancer suggest a significant contribution to HBOC susceptibility in the Spanish population. PALB2 screening may improve genetic counselling through prevention measures, pedigree management and PARP inhibitor therapy selection. Highlights • Spanish HBOC patients have been tested for PALB2 germline mutations. • One family carries a frameshift mutation that segregates within an early onset BOC. • PALB2 -deficient tumours may be sensitive to treatment with PARP inhibitors. • PALB2 germline mutations are present in 1% of BOC patients selected by family history. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
150. Video Education on Hereditary Breast and Ovarian Cancer (HBOC) for Physicians: an Interventional Study.
- Author
-
Krishnamachari, Bhuma, Rehman, Mahin, Cohn, Jason E., Chan, Vivian, Modi, Neil, Leitner, Ofri, Tangney, Kelly, O'Connor, April, Blazey, William, Koehler, Sharon, and Tegay, David
- Abstract
The National Comprehensive Cancer Network (NCCN) guidelines are the gold standard in hereditary cancer risk assessment, screening, and treatment. A minority of physicians follow NCCN guidelines for BRCA1 or BRCA2 mutations. This study assesses the impact of an interventional educational program on HBOC in terms of knowledge. Physicians were sent an invite to join either an intervention survey (web-training offered prior to the knowledge survey) or control survey (web-training offered after the knowledge survey). Sixty-nine physicians in the intervention arm and 67 physicians in the control arm completed the survey. The interventional group regularly answered items correctly at a higher frequency than the control group. For example, 64.71% (n = 44) of physicians in the intervention group knew that multi-gene testing does not have to include only highly penetrant genes compared to 32.84% (n = 22) of the control group (p < 0.01). Similar results were seen with other specific survey items. The current study is important in that it shows web-based education to be a feasible and effective modality for training on hereditary breast cancer. This type of education may be incorporated into CME programs and can be used as a foundation for further studies as well. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.